[Strontium ranelate's (Osseor) dual mode of action: increasing bone mass and decreasing bone resorption].
Strontium ranelate has unique dual mode of action on bone remodeling through increased bone formation and decreased bone resorption. As a consequence, there is increased bone mass and bone strength, leading to reduced number of vertebral and nonvertebral fractures. Although strontium bone distribution is heterogeneous, higher concentrations of strontium are found in younger bones. Long term treatment with strontium ranelate does not lead to any change in bone mineral distribution, mineral composition or crystal stability, nor is strontium accumulated in bone.
Kaliterna
Dusanka Martinović
DM
Odsjek za klinicku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinicki bolnicki centar Split, Soltanska 1, 2100 Split.
D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001862:Bone Resorption / Q000188:drug therapy*; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology; D013876:Thiophenes / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate